Diagnostic and Molecular Histopathology Core

摘要 在NIH/NCI U54资助(CA156735)和NIH/NIGMS P20资助(MD000175)的支持下，我们 用于建立诊断和分子组织病理学设施的指定空间和必要仪器 (DMHF)，北卡罗来纳州Julius L.Chambers生物医学/生物技术研究所(BBRI) 中央大学(NCCU)。在NCCU和Lineberger Complete之间的这一续订U54合作伙伴关系中 癌症中心(LCCC)，我们的DMHF有以下具体目标：(1)进一步开发一种诊断和 分子组织病理学实验室；(2)为这项资助的研究项目提供组织病理学服务 建议和其他健康差距研究；(3)在下列情况下支持出版物和批准申请 需要组织病理学专业知识；以及(4)培训学生、博士后和技术人员使用 用于研究和教育目的的组织病理学技术。总而言之，DMHF预计 为研究项目(完整项目1、完整项目3和试点项目2)提供坚实的技术支持 在U54奖助期和以后的教育。目标是确保在癌症方面的合作伙伴关系 NCCU与LCCC的差距研究取得成功。

Abstract With the support of NIH/NCI U54 grant (CA156735) and NIH/NIGMS P20 grant (MD000175), we have designated space and essential instruments to establish a Diagnostic and Molecular Histopathology Facility (DMHF) at the Julius L. Chambers Biomedical/Biotechnology Research Institute (BBRI) of the North Carolina Central University (NCCU). In this renewal U54 partnership between NCCU and Lineberger Comprehensive Cancer Center (LCCC), our DMHF has Specific Aims as follows: (1) To further develop a diagnostic and molecular histopathology laboratory; (2) To provide histopathological service to research projects in this grant proposal and other health disparity studies; (3) To support publications and grant applications when histopathology expertise is needed; and (4) To train students, postdocs and technical staff members to use histopathological techniques for both research and educational purposes. In summary, the DMHF is expected to provide solid technical support to research projects (Full Project 1, Full Project 3 and Pilot Project 2) and education during the U54 grant period and in the future. The goal is to ensure the partnership in cancer disparity research between NCCU and LCCC a success.